EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Antiseizure medication selection and retention for adult onset focal epilepsy in a Swedish health service region: A population‐based cohort study

David Larsson iD, Deala Mroué, Kerstin Andrén iD, Johan Zelano iD

Epilepsia · 2023

DOI: 10.1111/epi.17711 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia, 2023. Verfasst von David Larsson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Partial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Swedish state, Västra Götalandsregionen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Historically, approximately half of those with newly diagnosed epilepsy have responded to and tolerated the first antiseizure medication (ASM), but there are few contemporary real‐world data. Third‐generation ASMs have improved tolerability and are increasingly used according to prescription data. We aimed to describe current ASM selection and retention in adult onset focal epilepsy in western Sweden.

Methods

A multicenter retrospective cohort study was performed at five public neurology care providers in western Sweden (nearly complete coverage in the area). We reviewed 2607 medical charts and included patients diagnosed with nongeneralized epilepsy after January 1, 2020 who had a seizure onset after age 25 years (presumed focal onset) and were started on ASM monotherapy.

Results

A total of 542 patients (median age at seizure onset = 68 years, interquartile range = 52–77) were included. Most patients received levetiracetam (62%) or lamotrigine (35%), with levetiracetam being more common among men and those with structural causes or short epilepsy duration. During follow‐up (median = 471.5 days), 463 patients (85%) remained on the first ASM. Fifty‐nine (18%) patients discontinued levetiracetam, and 18 (10%) ended treatment with lamotrigine ( p = .010), most commonly because of side effects. In a multivariable Cox regression model, the discontinuation risk was higher for levetiracetam than lamotrigine (adjusted hazard ratio = 2.01, 95% confidence interval = 1.16–3.51). Significance Levetiracetam and lamotrigine were the dominating first ASMs for adult onset focal epilepsy in our region, indicating good awareness of problems with enzyme induction or teratogenicity of older drugs. The most striking finding is the high retention rates, perhaps reflecting a shift toward an older epilepsy population, higher tolerability of newer ASMs, or suboptimal follow‐up. The finding that treatment retention differed among patients receiving levetiracetam and lamotrigine aligns with the recent SANAD II results. It suggests lamotrigine may be underutilized in our region and that education efforts are needed to ensure it is considered the first choice more often.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsies, PartialHumansMaleSwedenFemaleMiddle AgedRetrospective StudiesAgedLevetiracetamCohort StudiesLamotrigineAdult

Stichwörter der Autor:innen

antiepileptic drugdiscontinuationlamotriginelevetiracetamseizurewithdrawal

Substanzen

AnticonvulsantsLevetiracetamLamotrigine

Autor:innen und Institutionen

  • Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
  • Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Wallenberg Center of Molecular and Translational Medicine, Gothenburg University, Gothenburg, Sweden.
  • Department of Neurology, Södra Älvsborg Hospital, Borås, Sweden.
  • Angered Hospital, Sjukhusen i Väster Hospital Group, Gothenburg, Sweden.

ORCID-Profile: David Larsson, Kerstin Andrén, Johan Zelano

Förderung

  • The Swedish state
  • Västra Götalandsregionen

Zitieren

APA

Larsson, D., Mroué, D., Andrén, K., & Zelano, J. (2023). Antiseizure medication selection and retention for adult onset focal epilepsy in a Swedish health service region: A population‐based cohort study. Epilepsia. https://doi.org/10.1111/epi.17711

Vancouver

Larsson D, Mroué D, Andrén K, Zelano J. Antiseizure medication selection and retention for adult onset focal epilepsy in a Swedish health service region: A population‐based cohort study. Epilepsia. 2023. doi:10.1111/epi.17711

BibTeX
@article{Larsson2023,
  author = {Larsson, David and Mroué, Deala and Andrén, Kerstin and Zelano, Johan},
  title = {Antiseizure medication selection and retention for adult onset focal epilepsy in a Swedish health service region: A population‐based cohort study},
  journal = {Epilepsia},
  year = {2023},
  doi = {10.1111/epi.17711}
}
Kostenlos starten →